Involvement of SRSF1 in Alternative Splicing of FPGS and Methotrexate Resistance in Children with Acute Lymphoblastic Leukemia

  • Inge van der Werf VU Medical Center
  • Jacqueline Cloos VU Medical Center

Abstract

Methotrexate (MTX) is a key component in treatment of childhood ALL. Impaired polyglutamation is a known mechanism of MTX-resistance. To date, a spectrum of splicing alterations was identified for folypoly-γ-glutamate synthetase (FPGS), the enzyme which catalyzes polyglutamation. The serine/arginine-rich splicing factor 1 (SRSF1) is involved in both constitutive and alternative splicing. We found an association between the expression of SRSF1 isoforms, ASF1 and ASF3, and alternative splice variants of FPGS. Moreover, in a subgroup of patients with deficient polyglutamation, the ratio of ASF3 to ASF1 was associated with survival. Therefore splice regulators are potential prognostic markers for both patient stratification and personalized medicine in childhood ALL.

References

1. Pui et al. (2012). Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood. 120:1165-1174

2. Assaraf, Y.G. (2007). Molecular basis of antifolate resistance. Cancer Metastasis Rev. 26:153-181

3. Rots et al. (1999). Leukemia in Methotrexate Accumulation and Polyglutamylation in Childhood Role of Folylpolyglutamate Synthetase and Folylpolyglutamate Hydrolase. Blood Journal. 93: 1677-1683

4. Stark et al. (2009). Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of
antifolate resistance in leukemia. Lymphoid Neoplasia. 113: 4362-4369

5. Unpublished data, Anna Wojtuszkiewicz et al.

6. Krainer et al. (2014). Emerging functions of SRSF1, splicing factor and oncoprotein, in RNA metabolism and cancer. Molecular Cancer research.

7. Zhu et al. (2000). Pre-mRNA splicing in the absence of an SR protein RS domain. Genes and development. 14:3166-3178

8. Zuo et al. (1993). Funtional domains of the human splicing factor ASF/SF2. The EMBO Journal. 12(12):4727-4737

9. Shaw et al. (2007) Deletion of the N-terminus of SF2/ASF permits RS-domain-independent pre-mRNA splicing. PLoS One. 2:e854

10. Franke et al. (2012). Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. Leukemia. 26, 757–768

11. Desmet et al. (2009). Human Splicing Finder. Nucleic Acid Research. 37(9):e67.

Author Biographies

Inge van der Werf, VU Medical Center
Dept. of Pediatric Oncology/Hematology Cancer Center Amsterdam, VUMC
Jacqueline Cloos, VU Medical Center
Dept. of Pediatric Oncology/Hematology Cancer Center Amsterdam, VUMC
How to Cite
VAN DER WERF, Inge; CLOOS, Jacqueline. Involvement of SRSF1 in Alternative Splicing of FPGS and Methotrexate Resistance in Children with Acute Lymphoblastic Leukemia. Student Undergraduate Research E-journal!, [S.l.], v. 1, nov. 2015. ISSN 2468-0443. Available at: <https://journals.open.tudelft.nl/index.php/sure/article/view/1037>. Date accessed: 22 may 2019.
Published
2015-11-20